[Muscularis mucosae invasion: prognostic factor for intravesical BCG immunotherapy failure for T1 bladder carcinoma]
| Autor: | Y, Nguyen-Huu, G, Delorme, J, Lillaz, I, Bedgedjian, I, Le Ray-Ferrières, E, Chabannes, S, Bernardini, G, Guichard, H, Bittard, F, Kleinclauss |
|---|---|
| Přispěvatelé: | Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Laboratoire d'anatomie pathologique [Besancon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Service d'Anatomie pathologique [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Saas, Philippe |
| Jazyk: | francouzština |
| Rok vydání: | 2012 |
| Předmět: |
[SDV.IMM] Life Sciences [q-bio]/Immunology
MESH : Retrospective Studies MESH : Aged MESH: Neoplasm Grading Cystectomy MESH : Neoplasm Invasiveness MESH: Prognosis MESH: Multivariate Analysis Humans [ SDV.IMM ] Life Sciences [q-bio]/Immunology Neoplasm Invasiveness MESH : BCG Vaccine MESH : Mucous Membrane Aged Retrospective Studies MESH: Aged MESH: Carcinoma in Situ Mucous Membrane MESH: Humans MESH : Prognosis MESH : Neoplasm Recurrence Local MESH : Humans MESH: Cystectomy MESH: Mucous Membrane MESH : Multivariate Analysis MESH: Retrospective Studies MESH : Follow-Up Studies MESH: Neoplasm Invasiveness MESH: Follow-Up Studies MESH : Disease Progression Prognosis MESH : Cystectomy MESH: Urinary Bladder Neoplasms MESH: BCG Vaccine MESH : Carcinoma in Situ Urinary Bladder Neoplasms MESH : Urinary Bladder Neoplasms Multivariate Analysis BCG Vaccine Disease Progression [SDV.IMM]Life Sciences [q-bio]/Immunology MESH: Disease Progression Neoplasm Grading Neoplasm Recurrence Local MESH: Neoplasm Recurrence Local Carcinoma in Situ MESH : Neoplasm Grading Follow-Up Studies |
| Zdroj: | Progrès en Urologie Progrès en Urologie, Elsevier Masson, 2012, 22 (5), pp.284-90. 〈10.1016/j.purol.2011.10.002〉 Progrès en Urologie, Elsevier Masson, 2012, 22 (5), pp.284-90. ⟨10.1016/j.purol.2011.10.002⟩ |
| ISSN: | 1166-7087 2405-5131 |
| DOI: | 10.1016/j.purol.2011.10.002〉 |
| Popis: | International audience; OBJECTIVES: To study the prognostic impact of muscularis mucosae (MM) invasion for pT1 bladder cancer treated by transurethral resection (TUR) and adjuvant Bacille Calmette-Guerin (BCG) intravesical immunotherapy. METHODS: Sixty-six patients treated by BCG intravesical instillations were substaged into pT1a and pT1b, regarding Muscularis Mucosae invasion. Tumor grade, associated carcinoma in situ (CIS), multifocality, tumoral size up to 3cm, BCG maintenance were noted. With a mean follow-up of 50.5±38 months, we studied recurrence, progression, overall and specific survival. Cox's model method was used for multivariate analysis. RESULTS: Tumor recurrence was observed in 30±7% and 43±10% (P=0.29) and tumor progression in 16.3±5% and 39±10% (P=0.04) for pT1a and pT1b. The rate of progression was higher (P=0.04) and progression free survival was decreased (P=0.04) for pT1b. Specific death rates were 11±5% and 21±9% (P=0.28), median overall survival was 80.9 [1.5-92] and 48.2 [12-93] months for pT1a and pT1b. Overall and specific survival weren't different between the two populations (P=0.38; P=0.3). Cystectomy rates were 2.3±2% and 30±9% for pT1a and PT1b (P=0.0006). For pT1a patients, recurrence (P=0.8) or progression rates (P=0.64) were no different regarding BCG maintenance immunotherapy but pT1b population had a better progression free survival with BCG maintenance than without (P=0.0051). Only CIS had prognostic value in multivariate analysis. CONCLUSIONS: Tumors with Muscularis Mucosae invasion have a higher risk of progression and BCG failure. Maintenance immunotherapy should be given to improve results with these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|